<DOC>
	<DOCNO>NCT00895089</DOCNO>
	<brief_summary>This clinical trial compare use moxifloxacin versus ceftriaxone treatment primary pyogenic liver abscess . The trial include nonpregnant adult present primary liver abscess base clinical diagnosis compute tomography . The trial aim determine whether use moxifloxacin effectively treat primary pyogenic liver abscess shorten hospitalization . This regimen additional benefit avoid nephrotoxic agent , aminoglycosides , use frequently treatment pyogenic liver abscess . Development antibiotic resistance colonize bacteria gastrointestinal tract also evaluate use stool culture .</brief_summary>
	<brief_title>Moxifloxacin Versus Ceftriaxone Treatment Primary Pyogenic Liver Abscess</brief_title>
	<detailed_description />
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Liver Abscess</mesh_term>
	<mesh_term>Liver Abscess , Pyogenic</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Age great equal 20 year . Clinical diagnosis liver abscess , support abdominal CT scan , document presence liver abscess , absence biliary tract stone ( except gallstone without biliary tract dilatation ) , biliary tract dilatation biliary tract tumor . Clinical diagnosis liver abscess include symptom fever , chill , right upper quadrant abdominal pain knock tenderness . Read , understand sign informed consent form . Presence septic metastatic infection CNS eye presentation . Cultures positive organism resistant study drug . APACHE II score great equal 20 . Coexistent disease consider likely affect outcome study ( e.g. , biliary tract stone malignancy ) . Patients rupture liver abscess Severe hepatic insufficiency ( ChildPugh C ) elevate serum transaminase ( GPT ) great 5 time upper limit normal . Patients pregnant lactating . Known hypersensitivity blactams fluoroquinolones . Known prolongation QT interval . Patients uncorrected hypokalemia . Patients receive class IA ( e.g. , quinidine , procainamide ) class III ( e.g. , amiodarone , sotalol ) antiarrhythmic agent Severe , lifethreatening disease life expectancy le 2 month . Pretreatment systemic antibacterial agent &gt; 24 hour prior enrollment within 5 day prior enrollment . Participated clinical investigational drug study within 4 week screen . Previously enter study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>liver abscess</keyword>
	<keyword>moxifloxacin</keyword>
	<keyword>ceftriaxone</keyword>
	<keyword>treatment</keyword>
</DOC>